Roche is 'well placed' for U.S. pricing tussle, CEO says

Worried about how mounting pricing pushback will affect Roche ($RHHBY)? Don't be, CEO Severin Schwan told Swiss newspaper Finanz und Wirtschaft. "Pressure will rise on drugs that are less sophisticated. But the United States will still offer an environment that supports and rewards real innovation," he pointed out. "Roche is well placed." And in the meantime, don't fret too much about the company's pipeline prospects, either, he said. With up to 6 new active pharmaceutical ingredients that could be approved within two years, "it is not at all the case anymore that everything has to succeed in terms of what lies ahead with the pipeline in the near term. If even a part succeeds, we are on course for further sustainable sales growth," he told the paper. More

Suggested Articles

Even as it gears up for phase 3 testing, Moderna has started commercial COVID-19 vaccine manufacturing, its CEO said.

Fitness guru and heart attack survivor Bob Harper is back again in AstraZeneca’s awareness effort to offer support and education to fellow survivors.

Taxpayers spent nearly $100 million to save remdesivir from the "scrapheap," a lawmaker wrote, and are being repaid with "price gouging."